Tafamidis
Last Updated: 11/08/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 863 publications
Cardiac amyloidosis: recognition, diagnosis and management.
Journal: Australian prescriber
Published: October 27, 2026
Carpal Tunnel Syndrome and Lumbar Spinal Stenosis: When to Suspect Amyloidosis and How to Proceed with the Diagnostic Work-up
Journal: Brain and nerve = Shinkei kenkyu no shinpo
Published: October 13, 2026
Single-cell gene networks nominate IKZF1 as an Alzheimer's disease microglial regulator.
Journal: Journal of Alzheimer's disease : JAD
Published: October 10, 2026
Stage-Specific Cost-Effectiveness of Early vs. Delayed Tafamidis for Transthyretin Amyloid Cardiomyopathy in Japan.
Journal: Circulation journal : official journal of the Japanese Circulation Society
Published: September 30, 2026
When Earlier Is Better But Still Not Cost-Effective - Reframing the Value of Tafamidis in Transthyretin Amyloid Cardiomyopathy.
Journal: Circulation journal : official journal of the Japanese Circulation Society
Published: September 30, 2026
Molecular imaging of TTR amyloidosis: New data.
Journal: Hellenic journal of nuclear medicine
Published: September 14, 2026
A trial emulation study indirectly comparing tafamidis and acoramidis in transthyretin amyloid cardiomyopathy: the ReplicATTR study.
Journal: Journal of comparative effectiveness research
Published: September 14, 2026
Proteomics Profiling Reveals Molecular Subtypes of Transthyretin Cardiac Amyloidosis.
Journal: Circulation. Heart failure
Published: September 10, 2026
Frailty is a mortality risk factor in tafamidis-treated patients with transthyretin cardiac amyloidosis.
Journal: Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis
Published: September 10, 2026
A Rare Cause of Recurrent Vomiting: Diagnosis and Management.
Journal: Gastroenterology
Published: August 28, 2026
Pathophysiology and Comprehensive Pharmacological Management of ATTR Cardiac Amyloidosis: Knowledge Gaps, Ongoing Clinical Trials, and Future Research Directions.
Journal: Pharmaceuticals (Basel, Switzerland)
Published: August 28, 2026
Continuous Vutrisiran Reduces Cardiovascular Events and Hospitalizations in Patients With Transthyretin Amyloidosis With Cardiomyopathy in the HELIOS-B One-Year Open Label Extension.
Journal: Journal of cardiac failure
Published: August 21, 2026
Last Updated: 11/08/2026